Crossmark

Outcomes of surveillance versus adjuvant treatment for patients with stage-I seminoma: a single-center experience

Crossref DOI link: https://doi.org/10.1007/s00345-023-04482-0

Published Online: 2023-06-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Akdag, Goncagul https://orcid.org/0000-0002-6221-0623
Alan, Ozkan https://orcid.org/0000-0002-6635-2012
Dogan, Akif https://orcid.org/0000-0003-4275-2414
Yuksel, Zeynep https://orcid.org/0000-0002-2929-5039
Yildirim, Sedat https://orcid.org/0000-0002-2423-6902
Kinikoglu, Oguzcan https://orcid.org/0000-0001-5983-3291
Kudu, Emre https://orcid.org/0000-0002-1422-5927
Surmeli, Heves https://orcid.org/0000-0003-1604-8466
Odabas, Hatice https://orcid.org/0000-0002-5757-4705
Yildirim, Mahmut Emre https://orcid.org/0000-0002-5360-5949
Turan, Nedim https://orcid.org/0000-0002-1140-8779
License Information

Text and Data Mining valid from 2023-06-23

Version of Record valid from 2023-06-23
More Information

Article History

Received: 7 March 2023

Accepted: 4 June 2023

First Online: 23 June 2023

Declarations

:

: None.

: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Kartal Dr. Lütfi Kırdar City Hospital, Istanbul, Türkiye, number 2022l5l4/238/13, November 29, 2022.